Provantage Corporate Finance advises XenoGesis on its sale to Sygnature Discovery

Project: XenoGesis
Sector: Healthcare
Deal Value: Undisclosed
Buyer: Sygnature Discovery

Provantage Corporate Finance is pleased to announce that it has advised the shareholders of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation, on its sale to Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider.

Since forming in 2011, XenoGesis, has achieved a strong track record of success through its novel consultative approach, focus on high quality science and forward-thinking methodologies.

In recent years, Sygnature has broadened its integrated drug discovery offering through strategic acquisitions and the latest acquisition of XenoGesis serves to meet both an increasing demand for its services and boost the company’s reach into the pre-clinical space. This acquisition effectively doubles the size of Sygnature’s DMPK department (established in 2015), broadening Sygnature’s discovery and development expertise, complementing its existing service-offering and adding new skills and capabilities.

Dr Simon Hirst, CEO and Founder at Sygnature Discovery commented “We have always had tremendous respect for the work that XenoGesis does and have a strong history of collaboration with them over the years. We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together.”

The companies are both located at BioCity in Nottingham, UK, fitting well with Sygnature’s driving ethos of having co-located, multi-disciplinary teams of expert research scientists, working efficiently together, facilitating seamless drug discovery and creating innovative solutions for its partners

Dr Richard Weaver, CEO and Founder at XenoGesis added: “Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers.”

Alex Thompson of Provantage Corporate finance commented, “It has been a real pleasure working with Richard and the XenoGesis team on this important transaction –  the team have built a fantastic business with huge growth potential and I look forward to seeing their continued success as part of Sygnature Discovery. It’s especially pleasing to complete such a transaction having only recently joined the Provantage team.”

David Browne, founding partner also added, “Richard and his team have built a great business in an exciting sector so we are very proud to have worked closely with them in helping secure this transaction. We are very confident that the business will go from strength to strength as part of Sygnature Discovery”